Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Nonalcoholic fatty liver disease and HIV infection.

Merriman RB.

Curr HIV/AIDS Rep. 2006 Sep;3(3):113-7. Review.

PMID:
16970837
2.

Hepatic steatosis in human immunodeficiency virus: a prospective study in patients without viral hepatitis, diabetes, or alcohol abuse.

Sterling RK, Smith PG, Brunt EM.

J Clin Gastroenterol. 2013 Feb;47(2):182-7. doi: 10.1097/MCG.0b013e318264181d.

3.

Nonalcoholic fatty liver disease and HIV infection.

Vallet-Pichard A, Mallet V, Pol S.

Semin Liver Dis. 2012 May;32(2):158-66. doi: 10.1055/s-0032-1316471. Epub 2012 Jul 3. Review.

PMID:
22760655
4.

From nonalcoholic fatty liver to nonalcoholic steatohepatitis and cirrhosis in HIV-infected patients: diagnosis and management.

Lemoine M, Serfaty L, Capeau J.

Curr Opin Infect Dis. 2012 Feb;25(1):10-6. doi: 10.1097/QCO.0b013e32834ef599. Review.

PMID:
22183113
5.

Human immunodeficiency virus is the major determinant of steatosis and hepatitis C virus of insulin resistance in virus-associated fatty liver disease.

Guaraldi G, Lonardo A, Ballestri S, Zona S, Stentarelli C, Orlando G, Carli F, Carulli L, Roverato A, Loria P.

Arch Med Res. 2011 Nov;42(8):690-7. doi: 10.1016/j.arcmed.2011.12.009. Epub 2012 Jan 4.

PMID:
22227046
6.

Nonalcoholic fatty liver disease: from steatosis to cirrhosis.

Farrell GC, Larter CZ.

Hepatology. 2006 Feb;43(2 Suppl 1):S99-S112. Review.

PMID:
16447287
7.

Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors.

Guaraldi G, Squillace N, Stentarelli C, Orlando G, D'Amico R, Ligabue G, Fiocchi F, Zona S, Loria P, Esposito R, Palella F.

Clin Infect Dis. 2008 Jul 15;47(2):250-7. doi: 10.1086/589294.

PMID:
18532884
8.

Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches.

Schuppan D, Schattenberg JM.

J Gastroenterol Hepatol. 2013 Aug;28 Suppl 1:68-76. doi: 10.1111/jgh.12212. Review.

PMID:
23855299
9.

Nutritional modulation of nonalcoholic fatty liver disease and insulin resistance: human data.

Yki-Järvinen H.

Curr Opin Clin Nutr Metab Care. 2010 Nov;13(6):709-14. doi: 10.1097/MCO.0b013e32833f4b34. Review.

PMID:
20842026
10.

Nonalcoholic fatty liver disease: pathology and pathogenesis.

Tiniakos DG, Vos MB, Brunt EM.

Annu Rev Pathol. 2010;5:145-71. doi: 10.1146/annurev-pathol-121808-102132. Review.

PMID:
20078219
11.

Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis.

Haga Y, Kanda T, Sasaki R, Nakamura M, Nakamoto S, Yokosuka O.

World J Gastroenterol. 2015 Dec 14;21(46):12989-95. doi: 10.3748/wjg.v21.i46.12989. Review.

12.

Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment.

Milić S, Stimac D.

Dig Dis. 2012;30(2):158-62. doi: 10.1159/000336669. Epub 2012 Jun 20. Review.

PMID:
22722431
13.

Influence of insulin resistance on hepatic fibrosis and steatosis in hepatitis C virus (HCV) mono-infected compared with HIV-HCV co-infected patients.

Halfon P, Pénaranda G, Carrat F, Bedossa P, Bourlière M, Ouzan D, Renou C, Tran A, Rosenthal E, Wartelle C, Delasalle P, Cacoub P.

Aliment Pharmacol Ther. 2009 Jul;30(1):61-70. doi: 10.1111/j.1365-2036.2009.03995.x. Epub 2009 Mar 9.

14.

Nonalcoholic Steatohepatitis and Hepatic Fibrosis in HIV-1-Monoinfected Adults With Elevated Aminotransferase Levels on Antiretroviral Therapy.

Morse CG, McLaughlin M, Matthews L, Proschan M, Thomas F, Gharib AM, Abu-Asab M, Orenstein A, Engle RE, Hu X, Lempicki R, Hadigan C, Kleiner DE, Heller T, Kovacs JA.

Clin Infect Dis. 2015 May 15;60(10):1569-78. doi: 10.1093/cid/civ101. Epub 2015 Feb 13.

15.

Evaluation and management of obesity-related nonalcoholic fatty liver disease.

Nugent C, Younossi ZM.

Nat Clin Pract Gastroenterol Hepatol. 2007 Aug;4(8):432-41. Review.

PMID:
17667992
16.

Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in HIV.

Rockstroh JK.

Curr HIV/AIDS Rep. 2017 Apr;14(2):47-53. doi: 10.1007/s11904-017-0351-2. Review.

PMID:
28284005
17.

Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity.

Fracanzani AL, Valenti L, Bugianesi E, Vanni E, Grieco A, Miele L, Consonni D, Fatta E, Lombardi R, Marchesini G, Fargion S.

J Hepatol. 2011 Jun;54(6):1244-9. doi: 10.1016/j.jhep.2010.09.037. Epub 2010 Nov 11.

18.

Non-alcoholic fatty liver disease, obesity and the metabolic syndrome.

Dietrich P, Hellerbrand C.

Best Pract Res Clin Gastroenterol. 2014 Aug;28(4):637-53. doi: 10.1016/j.bpg.2014.07.008. Epub 2014 Jul 11. Review.

PMID:
25194181
19.

Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis.

Bugianesi E, Marchesini G, Gentilcore E, Cua IH, Vanni E, Rizzetto M, George J.

Hepatology. 2006 Dec;44(6):1648-55.

PMID:
17133473
20.

Nonalcoholic Fatty liver disease and obesity.

Saadeh S.

Nutr Clin Pract. 2007 Feb;22(1):1-10. Review.

PMID:
17242448

Supplemental Content

Support Center